Canada Judgment Looms Large for Cannabis Companies

Wednesday, June 6, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

LAS VEGAS, June 6, 2018 /PRNewswire/ --

FN Media Group Presents Microcapspeculators.com News Commentary 

Four

days from now, Canada's Senate is expected to make a game-changing judgment on bill C-45, which is better-known as the Cannabis Act. If passed by the Senate, which is widely expected to happen, the Cannabis Act would
be one step closer to becoming law and, in the process, legalizing adult-use marijuana for Canadians. Mentioned in today's commentary includes: NightFood Holdings, Inc. (OTC: NGTF), INSYS Therapeutics, Inc. (NASDAQ: INSY), General Cannabis Corp. (OTC: CANN), CV Sciences Inc. (OTC: CVSI), and GW Pharmaceuticals plc (NASDAQ: GWPH) In becoming the first developed country in the world to legalize adult-use weed, Canada could be opening the door to $5 billion in added annual sales. This would come atop what the industry has already been generating from medical weed sales, as well as exports to countries where medical marijuana is legal. This upcoming news has investors more bullish than ever on the Marijuana industry. Here are a few public companies that offer investors the opportunity to enter this booming industry: NightFood Holdings, Inc. (OTCQB: NGTF), INSYS Therapeutics, Inc. (NASDAQ: INSY), General Cannabis Corp. (OTCQB: CANN), CV Sciences Inc. (OTCQB:CVSI), and GW Pharmaceuticals plc (NASDAQ: GWPH) NightFood Holdings, Inc. (OTCQB: NGTF)

Market Cap: $12.89M, current share price: $.32 

NightFood Holdings, Inc. (NGTF), a brand development company pioneering the projected multi-billion dollar nighttime nutrition category, last week announced that T3 Shamrock Media has been retained by the Company as agency of record for all public relations on behalf of the brand. T3 Shamrock Media was founded by Tim Sullivan, a publicist with over 25 years of experience with all types of media and global brands and former long-time director of publicity for The Dr. Oz Show. "We're very excited to have Tim and his team on board," commented Nightfood® CEO Sean Folkson. "They have an outstanding record working with brands in consumer health, food & beverage, and the sleep space, and they believe the media will love the Nightfood story." INSYS Therapeutics, Inc. (NASDAQ: INSY)

Market Cap: $493.04M, current share price: $6.68 

INSYS Therapeutics, Inc. (INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, announced that Saeed Motahari, president and chief executive officer, and Andy Long, chief financial officer, will present at the upcoming Jefferies 2018 Global Healthcare Conference Friday June 8th at 9:30 am. General Cannabis Corp. (OTCQB: CANN)

Market Cap: $118.08M, current share price: $3.33 

General Cannabis announced first quarter financial results earlier this month. For the first quarter of 2018, we reported revenues of $942,482, a 31% increase over 2017 first quarter revenues of $719,105. Thier existing operations in Colorado continue to prosper with Security, Marketing and Operations segments each showing strong year-over-year revenue growth. CV Sciences, Inc. (OTCQB: CVSI)

Market Cap: $191.88M, current share price: $2.12 

CV Sciences, Inc. (CVSI) announced that it entered into a binding and effective settlement agreement on May 31, 2018 with the Securities and Exchange Commission ("SEC") to fully and finally resolve all claims and matters related to the SEC's enforcement action against the Company. Michael J. Mona, Jr. concurrently settled all claims brought against him personally in this SEC matter. As part of the settlement, the Company and Mr. Mona neither admitted nor denied any wrongdoing. GW Pharmaceuticals plc (NASDAQ: GWPH)

Market Cap: $4.53B, current share price: $161.65 

GW Pharmaceuticals plc (GWPH), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced that The New England Journal of Medicine has published results from a Phase 3 study of cannabidiol oral solution in patients with Lennox-Gastaut syndrome (LGS), a rare, severe and difficult to treat form of childhood-onset epilepsy.1 Cannabidiol oral solution (CBD, Epidiolex®), is a pharmaceutical formulation of highly purified cannabidiol a cannabinoid lacking the high associated with cannabis. In this study, both evaluated doses of cannabidiol oral solution significantly reduced the monthly frequency of drop seizures compared to placebo in highly treatment-resistant patients when added to existing treatment. Naturals Project Inc., which was the first non-incumbent medical cannabis license granted by Health Canada, and Original BC Ltd., which is based in the Okanagan Valley, British Columbia . The Company has multiple international production and distribution platforms including in Germany , Israel and Australia . The Company intends to continue to rapidly expand its global footprint as it focuses on building an international iconic brand portfolio and develop disruptive intellectual property. Cronos Group is committed to building industry leading companies that transform the perception of cannabis and responsibly elevate the consumer experience. DISCLAIMER: Microcapspeculators.com (MS) is the source of the content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM,) and its online brand FinancialNewsMedia.com, is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with MS or any company mentioned herein. The commentary, views and opinions expressed in this release by MS are solely those of MS and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable MS and FNM for any investment decisions by their readers or subscribers. MS and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks included herein by MS. FNM was not compensated by any public company mentioned herein to disseminate this press release on behalf of MS.

MS Disclosure: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC, which owns Microcapspeculators.com, is not registered with Finra or any other financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC [and/or] Microcapspeculators.com does not have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC, which owns Microcapspeculators.com, is compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC has been compensated one thousand dollars cash for this article and twenty-two thousand total by Regal Consulting, LLC, for NGTF. NGTF and Regal Consulting, LLC were given an opportunity to edit information included in this article. This article is based solely on public information and the opinions of ACR Communication, LLC, which believes the news commentary to include accurate and complete information. ACR Communication, LLC, will not buy or sell any shares in stocks contained within this article for forty eight hours after this article's distribution. This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MS and FNM undertake no obligation to update such statements.

Media Contact: FN Media Group LLC e-mail: editor@financialnewsmedia.com +1-(954)345-0611

SOURCE Microcapspeculators



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store